Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 11, 2006. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, rather than a financial performance report.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to specific share transactions:
- Share Price: GBP 14.75 per Ordinary Share.
- Transaction Volume: 1 Ordinary Share per individual.
Material Changes
The filing reports changes in beneficial interests for two individuals under a Personal Equity Plan:
- Mr. R Bondy: Acquired 1 Ordinary Share on April 7, 2006.
- Mr. J Clarke: Acquired 1 Ordinary Share on April 7, 2006.
The Company and the individuals were advised of these transactions on April 10, 2006.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory notification pursuant to Disclosure Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the total number of shares held by Mr. R Bondy and Mr. J Clarke post-transaction to assess overall exposure.
- Confirm the current market price of GlaxoSmithKline plc Ordinary Shares relative to the GBP 14.75 transaction price.
- Review subsequent filings for broader financial performance data, as this document contains no operational metrics.